m6A-ATP,100mM Sodium Solution |
カタログ番号GB20006 |
m6A-ATPは、ATPの塩基修飾アナログであり、ED50値が17.250μMのアデノシン作動薬です。
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
m6A-ATP is an adenosine agonist with an ED50 value of 17.250 µM, and is a modulator of adenylate cyclase[1]. m6A-ATP inhibits hemoglobin accumulation and terminal maturation initiation in a concentration-dependent manner. In MEL cells, m6A-ATP reduces the mRNA of β-globin accumulated in the cytoplasm, affecting the structural integrity of this mRNA[2]. m6A-ATP slows down the growth rate of MEL cells, but basically does not inhibit cellular DNA synthesis and reduce cell viability and clonal potential[2]. Adenine, L-homocysteine, and/or L-methionine are all involved in the activated methylation cycle, enhancing m6A-ATP induced inhibition of initiation[3].
M6A modification is the most prevalent, abundant and conserved internal co-transcriptional modification in eukaryotic RNA, especially in higher eukaryotic cells[4]. M6A modification is considered as one of the post-transcriptional regulatory marks of different types of RNAs, including messenger RNAs (mRNAs), transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), circular RNAs (circRNAs), microRNAs (miRNAs) and long Noncoding RNAs (IncRNAs)[4]. M6A modification preferentially occurs within the consensus sequence RRACH (R = G or A; H = A, C or U) in the 3' UTRs and gene coding regions, and is involved in the processing and stability regulation of mRNA[5].
References:
[1]. Ribeiro JA and Sebastio AM. On the type of receptor involved in the inhibitory action of adenosine at the neuromuscular junction. Br J Pharmacol, 1985, 84(4):911-8.
[2]. Sinn P L and Sigmund CD. Human renin mRNA stability is increased in response to cAMP in Calu-6 cells. Hypertension, 1999, 33(3): 900-905.
[3]. Vizirianakis IS, Wong W and Tsiftsoglou AS. Analysis of the inhibition of commitment of murine erythroleukemia (MEL) cells to terminal maturation by N 6-methyladenosine. Biochemical pharmacology, 1992, 44(5): 927-936.
[4]. Shanshan Wang, et al. Dynamic regulation and functions of mRNA m6A modification. Cancer Cell International volume 22, Article number: 48 (2022)..
[5]. Zhao X, Yang Y, Sun BF, et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell research, 2014, 24(12): 1403-1419.
purity | >99.00% | Extinction Coefficient | |
Formula | C11H18N5O13P3(freeacid) | M.Wt | 521.20(freeacid) |
Salt Form | 濃度 | ||
Buffer | Storage | Store at -20°C | |
同義語 | Backbone | ||
Base Analog | Sugar Type | ||
Nucleotide Category |
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *